| RS2100699601 |
AGRN
|
Health Risk |
Pathogenic |
Congenital myasthenic syndrome 8, Congenital myasthenic syndrome 8 |
| RS2100699787 |
GNB1
|
Health Risk |
Likely pathogenic |
— |
| RS2100699881 |
GNB1
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 42 |
| RS2100699964 |
GNB1
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 42 |
| RS2100704859 |
DVL1
|
Health Risk |
Likely pathogenic |
Autosomal dominant Robinow syndrome 2, Autosomal dominant Robinow syndrome 2 |
| RS2100714986 |
DVL1
|
Health Risk |
Pathogenic |
Autosomal dominant Robinow syndrome 2, Autosomal dominant Robinow syndrome 2 |
| RS2100718483 |
DVL1
|
Health Risk |
Conflicting classifications of pathogenicity |
Autosomal dominant Robinow syndrome 2, Autosomal dominant Robinow syndrome 2 |
| RS2100726769 |
GNB1
|
Health Risk |
Pathogenic/Likely pathogenic |
Intellectual disability, autosomal dominant 42 |
| RS2100733763 |
NPHP4
|
Health Risk |
Likely pathogenic |
Nephronophthisis, Nephronophthisis |
| RS2100733826 |
NPHP4
|
Health Risk |
Pathogenic |
Nephronophthisis, Nephronophthisis |
| RS2100743480 |
PLOD1
|
Health Risk |
Pathogenic |
Ehlers-Danlos syndrome, kyphoscoliotic type 1 |
| RS2100743498 |
PLOD1
|
Health Risk |
Pathogenic |
Ehlers-Danlos syndrome, kyphoscoliotic type 1 |
| RS2100754171 |
PLOD1
|
Health Risk |
Likely pathogenic |
Ehlers-Danlos syndrome, Ehlers-Danlos syndrome |
| RS2100756997 |
PLOD1
|
Health Risk |
Pathogenic |
Ehlers-Danlos syndrome, kyphoscoliotic type 1 |
| RS2100758252 |
PLOD1
|
Health Risk |
Pathogenic |
Ehlers-Danlos syndrome, Ehlers-Danlos syndrome |
| RS2100758555 |
AGL
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100759240 |
AGL
|
Health Risk |
Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100759432 |
AGL
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease type III, Inborn genetic diseases |
| RS2100759667 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100760068 |
PLOD1
|
Health Risk |
Pathogenic |
Ehlers-Danlos syndrome, kyphoscoliotic type 1 |
| RS2100760610 |
AGL
|
Health Risk |
Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100761028 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS2100764790 |
PLOD1
|
Health Risk |
Likely pathogenic |
Ehlers-Danlos syndrome, kyphoscoliotic type 1 |
| RS2100765525 |
MTOR
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Inborn genetic diseases |
| RS2100768023 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100768428 |
AGL
|
Health Risk |
Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100768436 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100768726 |
AGL
|
Health Risk |
Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100768788 |
ATP13A2
|
Health Risk |
Pathogenic |
Kufor-Rakeb syndrome, Autosomal recessive spastic paraplegia type 78 |
| RS2100768875 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100768945 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100772715 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100778885 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100779184 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100779270 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100779419 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100779875 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 2 |
| RS2100779888 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100782122 |
MTOR
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Inborn genetic diseases |
| RS2100783138 |
ATP13A2
|
Health Risk |
Likely pathogenic |
Kufor-Rakeb syndrome, Autosomal recessive spastic paraplegia type 78 |
| RS2100785804 |
ATP13A2
|
Health Risk |
Likely pathogenic |
Autosomal recessive spastic paraplegia type 78, Autosomal recessive spastic paraplegia type 78 |
| RS2100788198 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100788460 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100788592 |
AGL
|
Health Risk |
Likely pathogenic |
— |
| RS2100789569 |
SKI
|
Health Risk |
Likely pathogenic |
Shprintzen-Goldberg syndrome, Shprintzen-Goldberg syndrome |
| RS2100790073 |
SKI
|
Health Risk |
Likely pathogenic |
Shprintzen-Goldberg syndrome, Shprintzen-Goldberg syndrome |
| RS2100790188 |
AGL
|
Health Risk |
Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100791272 |
SKI
|
Health Risk |
Pathogenic |
— |
| RS2100797119 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100797134 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease type 2, Maple syrup urine disease |
| RS2100799417 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100799447 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100802936 |
MFN2
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 2, Inborn genetic diseases |
| RS2100804114 |
AGL
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100804340 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100804954 |
RPE65
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100805193 |
RPE65
|
Health Risk |
Pathogenic |
Retinitis pigmentosa 20, Leber congenital amaurosis 2 |
| RS2100805351 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Leber congenital amaurosis 2 |
| RS2100806802 |
RPE65
|
Health Risk |
Likely pathogenic |
RPE65-related recessive retinopathy, RPE65-related recessive retinopathy |
| RS2100806806 |
RPE65
|
Health Risk |
Pathogenic |
Retinitis pigmentosa 20, Retinitis pigmentosa 20 |
| RS2100806889 |
RPE65
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100807036 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100807345 |
RPE65
|
Health Risk |
Likely pathogenic |
— |
| RS2100812695 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2100816844 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100817031 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100817106 |
ATP13A2
|
Health Risk |
Pathogenic |
Kufor-Rakeb syndrome, Kufor-Rakeb syndrome |
| RS2100817136 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100817917 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100818312 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100818414 |
AGL
|
Health Risk |
Pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100818444 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100818575 |
RPE65
|
Health Risk |
Pathogenic/Likely pathogenic |
Retinitis pigmentosa 20, Leber congenital amaurosis 2 |
| RS2100818777 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, RPE65-related recessive retinopathy |
| RS2100819151 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Leber congenital amaurosis 2 |
| RS2100819190 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100819197 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100819756 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Leber congenital amaurosis 2 |
| RS2100821707 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100821857 |
RPE65
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100821898 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100821984 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100822209 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2100822486 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2A2 |
| RS2100822581 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2100825216 |
AGL
|
Health Risk |
Likely pathogenic |
Glycogen storage disease type III, Glycogen storage disease type III |
| RS2100825988 |
MFN2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2100827350 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100827593 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100827985 |
RPE65
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100827990 |
RPE65
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100828545 |
RPE65
|
Health Risk |
Pathogenic |
Leber congenital amaurosis 2, Retinitis pigmentosa 20 |
| RS2100831413 |
RPE65
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 2, RPE65-related recessive retinopathy |
| RS2100831816 |
MFN2
|
Health Risk |
Likely pathogenic |
Tip-toe gait, Tip-toe gait |
| RS2100831900 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2100831955 |
MFN2
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2 |
| RS2100834154 |
RPE65
|
Health Risk |
Likely pathogenic |
Leber congenital amaurosis 2, Leber congenital amaurosis 2 |
| RS2100834784 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS2100840815 |
PIK3CD
|
Health Risk |
Pathogenic |
Immunodeficiency 14, Immunodeficiency 14 |
| RS2100841026 |
MFN2
|
Health Risk |
Pathogenic |
Severe early-onset axonal neuropathy due to MFN2 deficiency, Severe early-onset axonal neuropathy due to MFN2 deficiency |